Remove DNA Remove Trials Remove Virus
article thumbnail

Recombinant polyclonal drug trial for HBV gets FDA green light

Drug Discovery World

The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. In mouse models, GIGA-2339 neutralised and cleared HBV’s viral DNA along with its antigens.

article thumbnail

This week in drug discovery (18 -22 July)

Drug Discovery World

Junk DNA could lead to cancer, study says . Non-coding or ‘junk’ DNA could contribute to the development of certain cancers due to how it disrupts the replication of the genome, scientists have discovered.?? . US launches clinical trial for pandemic preparation . Infectious disease centre reaches major milestone?? .

DNA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Day Zero Antivirals for Future Pandemics

Codon

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus. Unsubscribe any time.

RNA 93
article thumbnail

Drug discovery deals highlight key growth areas

Drug Discovery World

GenomeFrontier partners with BioCina on CAR-T therapy CDMO BioCina and GenomeFrontier Therapeutics will partner on the development of virus-free CAR-T products for cancer treatment. BioCina will provide process development and GMP manufacturing for Minicircle DNA and Plasmid DNA.

DNA 130
article thumbnail

The Importance of Hazard Communications in Clinical Trials Involving Genetic Engineering

Advarra

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. This means site personnel do not have to review and sign a new SOP each time they submit a new mRNA protocol.

article thumbnail

Drug discovery and development trends – what will have most impact?

Drug Discovery World

Hosted by DDW and sponsored by DNA Script, join us for this free-to-attend roundtable to learn about the biggest opportunities for the future of drug discovery and development. What changes can we expect from clinical trials? Panellists will discuss the following questions: Where will the opportunities be in 2024?

DNA 130
article thumbnail

Join this exclusive DDW roundtable on drug discovery trends

Drug Discovery World

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ What changes can we expect from clinical trials? will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. How important will mRNA-based vaccines be in treating viruses and diseases such as cancer?

DNA 130